CNSP
Income statement / Annual
Last year (2025), Cns Pharmaceuticals Inc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Cns Pharmaceuticals Inc's net income was -$15.85 M.
See Cns Pharmaceuticals Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$3.31 K
|
$4.13 K
|
$11.76 K
|
$13.07 K
|
$11.10 K
|
$1.96 K
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
-$3.31 K
|
-$4.13 K
|
-$11.76 K
|
-$13.07 K
|
-$11.10 K
|
-$1.96 K
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$9.77 M
|
$9.29 M
|
$14.10 M
|
$9.30 M
|
$9.81 M
|
$5.06 M
|
$1.85 M
|
$21.27 K
|
$32.64 K
|
| General & Administrative Expenses |
$6.21 M
|
$0.00
|
$4.77 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$860.52 K
|
$437.92 K
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$255.45 K
|
| Selling, General & Administrative Expenses |
$6.21 M
|
$5.61 M
|
$4.77 M
|
$5.62 M
|
$4.67 M
|
$4.38 M
|
$1.98 M
|
$860.52 K
|
$182.47 K
|
| Other Expenses |
$0.00
|
$0.00
|
-$4.13 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$15.99 M
|
$14.90 M
|
$18.86 M
|
$14.92 M
|
$14.47 M
|
$9.44 M
|
$3.83 M
|
$881.79 K
|
$215.11 K
|
| Cost And Expenses |
$15.99 M
|
$14.90 M
|
$18.87 M
|
$14.93 M
|
$14.49 M
|
$9.45 M
|
$3.83 M
|
$881.79 K
|
$215.11 K
|
| Interest Income |
$153.79 K
|
$60.26 K
|
$27.69 K
|
$7.03
|
$9.29
|
$3.26
|
$44.23
|
$0.00
|
$0.00
|
| Interest Expense |
$15.23 K
|
$16.12 K
|
$13.81 K
|
$7.03 K
|
$9.29 K
|
$3.26 K
|
$44.23 K
|
$46.70 K
|
$4.26 K
|
| Depreciation & Amortization |
$3.92 K
|
$3.31 K
|
$4.13 K
|
$11.76 K
|
$13.07 K
|
$11.10 K
|
$1.96 K
|
$881.79 K
|
$516.25 K
|
| EBITDA |
-$15.83 M |
-$14.84 M |
-$18.86 M |
-$15.26 M |
-$14.47 M |
-$9.44 M |
-$3.83 M |
-$6.46 M |
$0.00 |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$136.00 K
|
$44.14 K
|
$13.88 K
|
-$341.17 K
|
-$9.29 K
|
-$3.26 K
|
-$44.23 K
|
-$6.51 M
|
-$4.26 K
|
| Income Before Tax |
-$15.85 M
|
-$14.86 M
|
-$18.85 M
|
-$15.27 M
|
-$14.50 M
|
-$9.46 M
|
-$3.88 M
|
-$7.39 M
|
-$219.36 K
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$15.85 M
|
-$14.86 M
|
-$18.85 M
|
-$15.27 M
|
-$14.50 M
|
-$9.46 M
|
-$3.88 M
|
-$7.39 M
|
-$526.47 K
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-35.75 |
-466.44 |
-150114 |
-336499 |
-495027 |
-512208 |
-212121 |
-404415 |
-11997 |
| EPS Diluted |
-35.75 |
-466.44 |
-150114 |
-336499 |
-495027 |
-512208 |
-212121 |
-404415 |
-11997 |
| Weighted Average Shares Out |
$443.37 K
|
$31.85 K
|
$125.58
|
$45.39
|
$29.28
|
$18.46
|
$18.28
|
$18.28
|
$18.28
|
| Weighted Average Shares Out Diluted |
$443.37 K
|
$31.85 K
|
$125.58
|
$45.39
|
$29.28
|
$18.46
|
$18.28
|
$18.28
|
$18.28
|
| Link |
|
|
|
|
|
|
|
|
|
